Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)

Summary

The primary objective is to evaluate the suitability of the challenge model in measuring the efficacy of MEDI-557 compared to placebo in healthy adult participants for the reduction in the incidence of RSV through 12 days post-RSV challenge with the RSV Memphis-37 strain.

Timeline

Start

2011-10-20

Primary completion

2011-12-03

Completion

2012-12-13

Outcome

Missed primary endpoint

Stopped (Enrollment): “The study was terminated as it was determined to not be feasible to complete enrollment and the study within the required timeline and budget.”

registry NUMBER Placebo: 66.7 percentage of participants NCT01475305 ↗

registry NUMBER MEDI-557: 0.0 percentage of participants NCT01475305 ↗

registry Relative Risk 0.00 (95% CI 0.00 to 2.05) NCT01475305 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MEDI-557	Monoclonal antibody	30 mg/kg	Intravenous

Indications